Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedAug 07, 2026
DataAggregated Company Financials
Companies20
  • 7D-8.8%
  • 3M2.3%
  • 1Y-4.1%
  • YTD-10.6%

Over the last 7 days, the Healthcare industry has dropped 10.0%, driven by Novo Nordisk declining 11%. As for the longer term, the industry's performance has been flat for the past year. As for the next few years, earnings are expected to grow by 2.9% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 07 Aug 2026DKK 1.7tDKK 470.7bDKK 141.6b21.2x12.3x3.7x
Sun, 05 Jul 2026DKK 1.9tDKK 469.2bDKK 147.1b20.9x12.8x4x
Tue, 02 Jun 2026DKK 1.7tDKK 468.5bDKK 147.0b20.7x11.8x3.7x
Thu, 30 Apr 2026DKK 1.5tDKK 447.6bDKK 130.0b17.5x11.8x3.4x
Sat, 28 Mar 2026DKK 1.4tDKK 447.8bDKK 130.1b16.6x10.9x3.2x
Mon, 23 Feb 2026DKK 1.8tDKK 447.8bDKK 131.0b18.7x13.6x4x
Wed, 21 Jan 2026DKK 2.2tDKK 453.8bDKK 136.9b17.9x16.2x4.9x
Fri, 19 Dec 2025DKK 1.8tDKK 453.8bDKK 136.9b17x13.5x4.1x
Sun, 16 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.4x13.8x4.2x
Tue, 14 Oct 2025DKK 2.2tDKK 447.8bDKK 141.8b17.9x15.3x4.8x
Thu, 11 Sep 2025DKK 2.1tDKK 447.4bDKK 141.7b19.7x14.5x4.6x
Sat, 09 Aug 2025DKK 1.9tDKK 432.1bDKK 131.0b28.7x14.4x4.3x
Mon, 07 Jul 2025DKK 2.5tDKK 422.9bDKK 124.4b30.8x19.7x5.8x
Wed, 04 Jun 2025DKK 2.5tDKK 423.8bDKK 124.7b30.5x20.3x6x
Fri, 02 May 2025DKK 2.4tDKK 409.3bDKK 121.3b23.2x20.1x6x
Sun, 30 Mar 2025DKK 2.6tDKK 409.5bDKK 121.3b22.8x21.3x6.3x
Tue, 25 Feb 2025DKK 3.4tDKK 410.0bDKK 121.4b28.6x27.9x8.3x
Thu, 23 Jan 2025DKK 3.1tDKK 387.4bDKK 111.3b28.7x27.9x8x
Sat, 21 Dec 2024DKK 3.1tDKK 387.4bDKK 111.3b28.7x28.2x8.1x
Mon, 18 Nov 2024DKK 3.7tDKK 387.3bDKK 111.3b31.6x33.3x9.6x
Wed, 16 Oct 2024DKK 4.1tDKK 372.1bDKK 107.2b36.6x38.6x11.1x
Fri, 13 Sep 2024DKK 4.7tDKK 372.0bDKK 107.1b35.1x43.6x12.5x
Sun, 11 Aug 2024DKK 4.7tDKK 370.3bDKK 107.0b35.9x43.6x12.6x
Tue, 09 Jul 2024DKK 5.0tDKK 355.3bDKK 106.2b35.5x46.7x14x
Thu, 06 Jun 2024DKK 4.7tDKK 355.3bDKK 106.2b36.4x44.4x13.3x
Sat, 04 May 2024DKK 4.3tDKK 354.7bDKK 106.3b33.9x40.9x12.3x
Mon, 01 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Wed, 28 Feb 2024DKK 4.3tDKK 340.0bDKK 98.9b37.9x43.6x12.7x
Fri, 26 Jan 2024DKK 3.7tDKK 320.5bDKK 90.0b35x41.6x11.7x
Sun, 24 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.2x11.3x
Tue, 21 Nov 2023DKK 3.6tDKK 320.4bDKK 90.0b33.8x40.5x11.4x
Thu, 19 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b28.6x44.6x12x
Sat, 16 Sep 2023DKK 3.6tDKK 305.5bDKK 82.2b35.9x43.8x11.8x
Mon, 14 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b41.3x40.8x11x
Price to Earnings Ratio

40.8x


Total Market Cap: DKK 3.3tTotal Earnings: DKK 81.0bTotal Revenue: DKK 301.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 28.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.3x which is lower than its 3-year average PE of 28.4x.
  • The 3-year average PS ratio of 8.3x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 20% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-4.33%
Healthcare-8.75%
Biotech2.26%
Healthtech-0.19%
Medical Equipment-1.54%
Life Sciences-3.95%
Healthcare Services-7.52%
Pharma-10.74%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.8x.
    • Analysts are expecting annual earnings growth of 20.4%, which is higher than its past year's earnings growth of 5.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.8% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.88k1.8%
+DKK 2.0b		29.8%PE21.6x
ZEAL Zealand PharmaDKK 328.307.7%
+DKK 1.6b		0.9%PE3.6x
EMBLA Embla Medical hfDKK 28.951.2%
+DKK 149.1m		-7.2%PE20.2x
AMBU B AmbuDKK 73.100.6%
+DKK 118.7m		-20.2%PE40.4x
VIRO ViroGatesDKK 10.9020.4%
+DKK 17.2m		-2.7%PS11.2x

Latest News

NOVO B
DKK 293.60
Novo Nordisk
7D
-11.3%
1Y
-4.9%
ALK B
DKK 220.20
ALK-Abelló
7D
-3.0%
1Y
19.0%
GUBRA
DKK 362.00
Gubra
7D
-3.4%
1Y
0.2%
DEMANT
DKK 281.00
Demant
7D
-1.6%
1Y
10.8%
Narrative Update • Aug 04

DEMANT: Future Returns Will Hinge On Executing Margin And Revenue Mix Improvements

The analyst price target for Demant has moved from DKK 251 to DKK 277, as analysts factor in updated assumptions on revenue growth, margins and valuation following a mix of target hikes and rating changes across recent research. Analyst Commentary Recent research on Demant shows a mix of optimism and caution, with higher price targets sitting alongside more neutral ratings.
CHEMM
DKK 415.00
ChemoMetec
7D
-4.4%
1Y
-17.5%
HLUN B
DKK 41.52
H. Lundbeck
7D
-1.1%
1Y
19.2%
GMAB
DKK 1,877.00
Genmab
7D
1.8%
1Y
29.8%
EMBLA
DKK 28.95
Embla Medical hf
7D
1.2%
1Y
-7.2%
Analysis Article • Jul 24

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
ZEAL
DKK 328.30
Zealand Pharma
7D
7.7%
1Y
0.9%
Narrative Update • Jul 23

ZEAL: Future Returns Will Hinge On Obesity Pipeline Execution Timing

The updated analyst price target for Zealand Pharma moves to DKK 300 from DKK 400. This reflects a more cautious stance as analysts point to fewer near term catalysts, lower peak sales expectations for petrelintide and survodutide, and a higher assumed discount rate and future P/E in their models.
AMBU B
DKK 73.10
Ambu
7D
0.6%
1Y
-20.2%
Narrative Update • Jul 15

AMBU B: Margin Resilience And Competitive Response Are Expected To Drive Future Upside

The analyst price target for Ambu has been cut from DKK 138.0 to DKK 116.4, as analysts adopt more cautious assumptions around competition, growth, margins, discount rate and future P/E following recent bearish research updates. Analyst Commentary Recent research on Ambu has leaned more cautious, with some price targets and ratings adjusted to reflect concerns about competition and the near term outlook.
COLO B
DKK 426.10
Coloplast
7D
-2.3%
1Y
-29.7%
Narrative Update • Jul 15

COLO B: Recent P/E Reset Will Create Upside Opportunity

Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.
BAVA
DKK 175.00
Bavarian Nordic
7D
-2.2%
1Y
-26.5%
NNIT
DKK 38.30
NNIT
7D
0.1%
1Y
-41.2%
VIRO
DKK 10.90
ViroGates
7D
20.4%
1Y
-2.7%
PEG
DKK 0.089
Pharma Equity Group
7D
1.1%
1Y
-27.9%